The Accelerating Cancer Cures Advisory Committee is comprised of senior oncology leaders in the collaborating companies. A valuable resource for Damon Runyon scientists, committee members are available for discussions and advice about the process of translating discoveries into therapeutics.

Chair

Richard B. Gaynor, MD
President of Research and Development
Neon Therapeutics

Kaitlin E. Browman, PhD, MBA
Senior Director of Discovery Strategic Portfolio Management
AbbVie Inc.

I-Fen Chang, PharmD
US Oncology Therapeutic Head
Amgen, Inc.

Kimberly L. Blackwell, MD
Vice President of Early Phase Clinical Development and Immuno-Oncology
Eli Lilly and Co.

Nancy Valente, MD
Vice President of Global Hematology Development
Genentech, Inc.

Nicholas Haining, BM, BCh
Vice President of Discovery Oncology
Merck and Co., Inc.

Eric H. Rubin, MD
Senior Vice President and Therapeutic Area Head
Oncology Early Development
Merck and Co., Inc.

Glenn Dranoff, MD
Global Head of Exploratory Immuno-Oncology
Novartis Institutes for BioMedical Research

Jeffrey A. Engelman, MD, PhD
Vice President and Global Head of Oncology
Novartis Institutes for BioMedical Research

  • You can support our innovative researchers.